AR132774A1 - Composiciones farmacéuticas - Google Patents
Composiciones farmacéuticasInfo
- Publication number
- AR132774A1 AR132774A1 ARP240101316A ARP240101316A AR132774A1 AR 132774 A1 AR132774 A1 AR 132774A1 AR P240101316 A ARP240101316 A AR P240101316A AR P240101316 A ARP240101316 A AR P240101316A AR 132774 A1 AR132774 A1 AR 132774A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- dcpa
- mcc
- pyrrolo
- pyrimidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente memoria descriptiva se relaciona con composiciones farmacéuticas que comprenden el Compuesto [I] ((S)-4-amino-N-(1-(4-clorofenil)-3-hidroxipropil)-1-(7H-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida), celulosa microcristalina (MCC) y fosfato de dicalcio anhidro (DCPA), por ejemplo, en comprimidos con propiedades de liberación inmediata.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23175788 | 2023-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132774A1 true AR132774A1 (es) | 2025-07-30 |
Family
ID=86605004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101316A AR132774A1 (es) | 2023-05-26 | 2024-05-24 | Composiciones farmacéuticas |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4719359A1 (es) |
| JP (1) | JP2026518000A (es) |
| KR (1) | KR20260016534A (es) |
| CN (1) | CN121175036A (es) |
| AR (1) | AR132774A1 (es) |
| AU (1) | AU2024279893A1 (es) |
| CL (1) | CL2025003668A1 (es) |
| CO (1) | CO2025018521A2 (es) |
| CR (1) | CR20250538A (es) |
| DO (1) | DOP2025000289A (es) |
| IL (1) | IL324773A (es) |
| MX (1) | MX2025014102A (es) |
| PE (1) | PE20260438A1 (es) |
| TW (1) | TW202510865A (es) |
| WO (1) | WO2024245953A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| WO2022147519A1 (en) * | 2021-01-04 | 2022-07-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of capivasertib and process for preparation thereof |
| CN119278041A (zh) * | 2022-03-31 | 2025-01-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体(egfr)酪氨酸激酶抑制剂 |
-
2024
- 2024-05-24 CR CR20250538A patent/CR20250538A/es unknown
- 2024-05-24 TW TW113119333A patent/TW202510865A/zh unknown
- 2024-05-24 KR KR1020257043170A patent/KR20260016534A/ko active Pending
- 2024-05-24 CN CN202480034498.5A patent/CN121175036A/zh active Pending
- 2024-05-24 PE PE2025002816A patent/PE20260438A1/es unknown
- 2024-05-24 WO PCT/EP2024/064426 patent/WO2024245953A1/en not_active Ceased
- 2024-05-24 JP JP2025568713A patent/JP2026518000A/ja active Pending
- 2024-05-24 AU AU2024279893A patent/AU2024279893A1/en active Pending
- 2024-05-24 IL IL324773A patent/IL324773A/en unknown
- 2024-05-24 AR ARP240101316A patent/AR132774A1/es unknown
- 2024-05-24 EP EP24729794.8A patent/EP4719359A1/en active Pending
-
2025
- 2025-11-21 DO DO2025000289A patent/DOP2025000289A/es unknown
- 2025-11-24 CL CL2025003668A patent/CL2025003668A1/es unknown
- 2025-11-25 MX MX2025014102A patent/MX2025014102A/es unknown
- 2025-12-23 CO CONC2025/0018521A patent/CO2025018521A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025014102A (es) | 2026-01-07 |
| CN121175036A (zh) | 2025-12-19 |
| TW202510865A (zh) | 2025-03-16 |
| CO2025018521A2 (es) | 2026-01-13 |
| IL324773A (en) | 2026-01-01 |
| PE20260438A1 (es) | 2026-02-19 |
| WO2024245953A1 (en) | 2024-12-05 |
| EP4719359A1 (en) | 2026-04-08 |
| DOP2025000289A (es) | 2026-01-15 |
| AU2024279893A1 (en) | 2026-01-22 |
| CR20250538A (es) | 2026-04-21 |
| JP2026518000A (ja) | 2026-06-02 |
| KR20260016534A (ko) | 2026-02-03 |
| CL2025003668A1 (es) | 2026-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008003023A1 (es) | (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer. | |
| UY39296A (es) | Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen | |
| AR116797A1 (es) | Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricación e intermediario al mismo | |
| UY29410A1 (es) | Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones. | |
| GT200600246A (es) | Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberacion modificada | |
| CO6150163A2 (es) | Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina | |
| ECSP11010960A (es) | Formulación farmacéutica 514 | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| AR065802A1 (es) | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas | |
| PE20080698A1 (es) | Composiciones farmaceuticas de inhibidores de dpp iv | |
| PE20240050A1 (es) | Inhibidores de cdk2 y metodos de uso de los mismos | |
| UY39094A (es) | Composición farmacéutica que comprende compuesto derivado de bencimidazol | |
| MY175052A (en) | Crystalline forms of (s) -4-amino-n- (1- (4 - chlorophenyl) - 3 - hydroxypropyl) -1- (7h - pyrrolo [2, 3-d] pyrimidi n-4-yl) piperidine-4-carboxamide | |
| CL2024001679A1 (es) | Formas en estado sólido de un inhibidor de fgfr | |
| UY29325A1 (es) | Nuevos derivados de 2 - amino-piridina | |
| MX2024008413A (es) | Compuestos macrocíclicos y uso como inhibidores de cinasas. | |
| CO2025018521A2 (es) | Composiciones farmacéuticas | |
| MX2023006284A (es) | Composicion farmaceutica de agonistas duales de glp-1/glp-2. | |
| CO2022016378A2 (es) | Formulaciones farmacéuticas | |
| UY29361A1 (es) | Pirroles e imidazoles sustituídos, composiciones que los contienen, procedimiento de fabricación y utilización | |
| DOP2019000099A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos | |
| CO2021014253A2 (es) | Formulación de tableta vaginal | |
| AR043173A1 (es) | Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular | |
| PE20070084A1 (es) | Proceso para la sintesis de 5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-bencenamina | |
| ECSP23089201A (es) | Nueva formulación para inyección que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina |